This funding supports Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers. It aims to improve patient access to promising treatments, provide researchers innovative access to medicines and technologies, and generate early safety and efficacy evidence. Supported trial designs include basket, umbrella, adaptive, and decentralised trials.
Eligibility criteria are not specified for this funding opportunity.
